Sensei Biotherapeutics’ (FTH) “Buy” Rating Reiterated at BTIG Research

BTIG Research reissued their buy rating on shares of Sensei Biotherapeutics (NASDAQ:FTH) in a research report released on Thursday morning,Benzinga reports. The firm currently has a $55.00 price objective on the stock.

A number of other equities research analysts also recently commented on FTH. Citigroup assumed coverage on shares of Sensei Biotherapeutics in a report on Friday, May 22nd. They set a “buy” rating and a $55.00 price target for the company. Zacks Research raised shares of Sensei Biotherapeutics to a “hold” rating in a research note on Tuesday, April 21st. Loop Capital set a $50.00 target price on shares of Sensei Biotherapeutics in a research report on Thursday, May 28th. HC Wainwright assumed coverage on shares of Sensei Biotherapeutics in a research note on Monday, June 22nd. They issued a “buy” rating and a $60.00 target price for the company. Finally, Weiss Ratings assumed coverage on Sensei Biotherapeutics in a report on Wednesday, June 17th. They issued a “sell (d-)” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $54.50.

Sensei Biotherapeutics Trading Down 0.3%

FTH opened at $25.87 on Thursday. The firm has a market cap of $34.67 million, a P/E ratio of -0.18 and a beta of -0.26. Sensei Biotherapeutics has a 52 week low of $6.32 and a 52 week high of $37.90.

Sensei Biotherapeutics (NASDAQ:FTH) last posted its quarterly earnings data on Friday, May 15th. The company reported ($131.45) EPS for the quarter. Equities analysts predict that Sensei Biotherapeutics will post -16.61 earnings per share for the current fiscal year.

Insider Transactions at Sensei Biotherapeutics

In other news, CFO Brian C. Stephenson bought 9,391 shares of the firm’s stock in a transaction dated Wednesday, June 24th. The stock was acquired at an average price of $26.13 per share, for a total transaction of $245,386.83. Following the acquisition, the chief financial officer owned 26,804 shares of the company’s stock, valued at $700,388.52. This trade represents a 53.93% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Anand Kiran Parikh bought 2,806 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The shares were acquired at an average cost of $19.76 per share, with a total value of $55,446.56. Following the transaction, the chief executive officer owned 764,234 shares in the company, valued at approximately $15,101,263.84. This represents a 0.37% increase in their position. The SEC filing for this purchase provides additional information. Insiders have bought a total of 49,494 shares of company stock worth $1,188,822 in the last three months. 7.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Sensei Biotherapeutics

Several institutional investors have recently bought and sold shares of FTH. Renaissance Technologies LLC increased its position in shares of Sensei Biotherapeutics by 10.6% in the fourth quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock worth $123,000 after acquiring an additional 1,100 shares in the last quarter. Bank of America Corp DE lifted its holdings in shares of Sensei Biotherapeutics by 10,692.5% during the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after acquiring an additional 32,719 shares in the last quarter. Stempoint Capital LP acquired a new position in shares of Sensei Biotherapeutics during the 1st quarter valued at $4,188,000. Finally, Vivo Capital LLC purchased a new stake in Sensei Biotherapeutics during the 1st quarter worth $22,758,000. 10.50% of the stock is currently owned by hedge funds and other institutional investors.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.